Commitment to Care
Trusted Since 1985*

*FDA-approved in 1985, the first GnRHa for the treatment of advanced prostate cancer.2
Lucas, age 64
Semi-retired financial analyst, passionate cook,
husband and father

Not an actual patient.

LUPRON DEPOT, an androgen deprivation therapy (ADT), has been a pioneer in the treatment of advanced prostate cancer.2

A Wealth of Experience

Our commitment to your patients will be as strong tomorrow as it is today.

The number one prescribed icon

#1 Prescribed

America’s most-prescribed
GnRHa3†‡

Calendar icon

35+ Years

The most clinical experience of
any GnRHa on the market2§

Group of men icon

Millions of injections
administered4||

†Based on IQVIA NSP data.
‡GnRHa=Gonadotropin-releasing hormone agonist.
§FDA approved for advanced prostate cancer in 1985.2
||Based on MEU sales data.
Lucas, a LUPRON DEPOT patient, standing next to ‘The number one prescribed GnRHa’ badge Lucas, a LUPRON DEPOT patient, standing next to ‘The number one prescribed GnRHa’ badge Lucas, a LUPRON DEPOT patient, standing next to ‘The number one prescribed GnRHa’ badge
†Based on IQVIA NSP data.
‡GnRHa=Gonadotropin-releasing hormone agonist.
§FDA approved for advanced prostate cancer in 1985.2
||Based on MEU sales data.

A Number of Firsts

From day 1, LUPRON DEPOT has been committed to the treatment of advanced prostate cancer.

1985

In 1985, LUPRON DEPOT became the first approved GnRH agonist for the palliative treatment of advanced prostate cancer

1998

Manufactured injection-ready, GnRHa-prefilled,
dual-chamber syringe

2003

Introduced built-in safety mechanism—LuproLoc®

2007

Created LuproLink® Inventory Management system for
LUPRON DEPOT inventory

2014

Support PLUS program launched: A program that supports your patients with benefits verification and reimbursement support

2019

Dosage and administration section of the label updated to include continued treatment in patients who develop non-metastatic castration-resistant prostate cancer (nmCRPC)1

2021

Support PLUS Specialists* offer patients personalized, one-on-one support from a dedicated LUPRON DEPOT specialist

*Support PLUS Specialists are provided by AbbVie and do not work under the direction of a healthcare professional (HCP) or give medical advice. They are trained to direct patients to speak with their HCP for treatment-related advice, including further referrals.  

Coverage and Affordability

We are committed to making LUPRON DEPOT accessible and affordable for patients.

>99%
of patients

LUPRON DEPOT is covered* for >99% of patients with commercial insurance, Medicaid, and Medicare Part B combined5

100%
covered

LUPRON DEPOT is covered* by 100% of Medicare Part B plans5†

Overview of Medicare Part B and D

Medicare
Part B

Most LUPRON DEPOT patients are covered* through Medicare Part B. 

Part B is a medical benefit that covers services such as in-office administration for medications like LUPRON DEPOT 

Part B may offer lower out-of-pocket costs for patients compared with Part D or commercial pharmacy benefits

Medicare
Part D

Part D is a prescription drug benefit that covers medications dispensed through a pharmacy

Part D may have higher out-of-pocket costs than Part B

*

Covered means the product is not NDC (National Drug Code) blocked as of 2020. Restrictions may apply. Percentage covered reflects known status for medical insurance coverage only.
†

For those Commercial and Medicare plans that report coverage data; excludes plans and payors with unknown coverage. 

Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

"...decades of experience in using LUPRON DEPOT in my practice continues to reinforce my confidence in prescribing it as my first choice for patients with advanced prostate cancer"

WATCH DR SPITZ'S VIDEO
RFID=radio-frequency identification.
#CRPC=castration-resistant prostate cancer.
LUPRON DEPOT offers a number of KEY features